A new study published today in the journal Genes & Development reveals a gene that normally suppresses the formation of tumors but is reprogrammed at the onset of acute promyelocytic leukemia (APL), an aggressive type of blood cancer that is responsible for 5-15% of all types of leukemia.
Researchers identify therapeutic target for aggressive blood cancer
A new study published today in the journal Genes & Development reveals a gene that normally suppresses the formation of tumors but is reprogrammed at the onset of acute promyelocytic leukemia (APL), an aggressive type of blood cancer that is responsible for 5-15% of all types of leukemia.